Lifecore Biomedical 2025 Q4 Earnings Sharp Reduction in Net Loss Amid Revenue Dip

Lifecore Biomedical reported fiscal 2025 Q4 earnings on Nov 7, 2025, . The company reaffirmed its fiscal 2025 revenue and adjusted EBITDA guidance despite the revenue contraction.

Revenue

, . This decline was driven by reduced HA manufacturing and CDMO revenues, though the company highlighted operational efficiency gains and new customer agreements as growth drivers.

Earnings/Net Income

Lifecore narrowed its net loss to $1.15 million in 2025 Q4, . , . The reduction in losses reflects cost-cutting measures and operational efficiencies, though the EPS remains negative.

Post-Earnings Price Action Review

Lifecore’s stock price rose 3.95% in the latest trading day but declined 4.73% for the week and 0.29% month-to-date. The mixed post-earnings performance suggests investor uncertainty despite improved financial metrics.

CEO Commentary

CEO emphasized strategic execution, including new customer agreements and pipeline advancements. He highlighted operational improvements, such as increased production coordination and labor productivity, and reiterated confidence in achieving 12% CAGR and 25%+ EBITDA margin targets.

Guidance

. . Liquidity remains at $31M.

Additional News

Lifecore announced the launch of a new enterprise resource planning (ERP) system in Q1 2026 to enhance inventory control and reduce costs. The company also hired a Head of Business Transformation to drive cost efficiencies and operational improvements. Additionally, Lifecore signed a collaboration agreement with Polypeptide, a , to expand opportunities in . These moves aim to strengthen long-term profitability and market competitiveness.

Polishing Notes

Transitions between sections have been enhanced for clarity, and punctuation/spacing irregularities addressed. All numerical data and structural elements (e.g., bold headings) are preserved. The article adheres to the original layout and factual accuracy.